Macrophages present a central line of defense against cancer by preventing inflammation and eliminating tumor cells. However, tumor-associated-macrophages (TAMs) at times protect the tumor from immune responses and facilitate its growth. Elevated levels of TAMs are commonly associated with poor outcomes, and depleting them can prevent cancer progression and metastasis. However, the signals mediating these opposing macrophage identities are unknown. Dr. Duttke aims to figure out what makes TAMs different from normal, anti-cancer macrophages by analyzing macrophages/TAMs in tumors and healthy patient tissues. Understanding the pathways linked to TAM identity may single out targets for therapies aiming to suppress TAMs and aid tumor elimination.
University of California, San Diego | All Cancers, Lung Cancer | 2015 | Christopher K. Glass, M.D., Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
We spoke with Dr. Yvonne Chen to learn more about her work in chemical engineering to fight cancer and what she hopes to accomplish during the next five years as a CRI Lloyd J. Old STAR.
We round up the latest immunotherapy for pancreatic cancer news and research from the scientists, physicians, and patients changing the future of pancreatic cancer treatment.